Abstract
Alzheimer disease (AD) is the most common cause of dementia. In the past decade, many advances in the understanding of the etiology of AD have been reported. Familial early onset AD is a heterogeneous disorder that can be caused by mutations in at least three different genes. Current studies are focused on identifying genetic risk factors for late onset AD. In this article, the authors will review the progress in understanding the pathogenic implications of the genes mutated in familial early onset AD and the mapping studies to identify additional genes involved in late-onset AD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Alzheimer A: Über eigenartige Krankheitsfälle des späteren Alters. A Zschr ges Neurol Psychiat 1911, 4:356–385.
Rocca WA, Hofman A, Brayne C, et al.: Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 1991, 30:381–390.
Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987, 76:465–479.
Ritchie K, Kildea D: Is senile dementia “age-related” or “aging-related?” Evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995, 346:931–934.
Osuntokun B, Ogunniyi A, Lekauwa U: Alzheimer’s disease in Nigeria. Afr J Med Sci 1992, 2171–2177.
Chandra V, Pandav R, Dodge HH, et al.: Incidence of Alzheimer’s disease in a rural community in India: the Indo-US study. Neurology 2001, 57:985–989.
Zhang MY, Katzman R, Salmon D, et al.: The prevalence of dementia and Alzheimer’s disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990, 27:428–437.
Barclay LL, Zemcov A, Blass JP, Sansone J: Survival in Alzheimer’s disease and vascular dementias. Neurology 1985, 35:834–840.
Akesson HO: A population study of senile and arteriosclerotic psychoses. Hum Hered 1969, 19:546–566.
Molsa PK, Marttila RJ, Rinne UK: Epidemiology of dementia in a Finnish population. Acta Neurol Scand 1982, 65:541–552.
Braak H, Braak E: Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol (Berl) 1991, 82:239–259.
Selkoe DJ: Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994, 17:489–517.
Games D, Adams D, Alessandrini R, et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F betaamyloid precursor protein. Nature 1995, 373:523–527.
Goedert M, Crowther RA: Amyloid plaques, neurofibrillary tangles and their relevance for the study of Alzheimer’s disease. Neurobiol Aging 1989, 10:405–406.
Wang JZ, Wu Q, Smith A, et al.: Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett 1998, 436:28–34.
Bondareff W, Mountjoy CQ, Roth M, Hauser DL: Neurofibrillary degeneration and neuronal loss in Alzheimer’s disease. Neurobiol Aging 1989, 10:709–715.
Massoud F, Devi G, Stern Y, et al.: A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Arch Neurol 1999, 56:1368–1373.
Holmes C, Cairns N, Lantos P, Mann A: Validity of current clinical criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999, 17:445–450.
Galasko D, Chang L, Motter R, et al.: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998, 55:937–945.
Hulstaert F, Blennow K, Ivanoiu A, et al.: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555–1562.
Andreasen N, Minthon L, Davidsson P, et al.: Evaluation of CSFtau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373–379.
Jensen M, Schroder J, Blomberg M, et al.: Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann Neurol 1999, 45:504–511.
Ertekin-Taner N, Graff-Radford N, Younkin LH, et al.: Heritability of plasma amyloid beta in typical late-onset Alzheimer’s disease pedigrees. Genet Epidemiol 2001, 21:19–30.
Han X, Fagan AM, Cheng H, et al.: Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol 2003, 54:115–119.
Ezquerra M, Carnero C, Blesa R, et al.: A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures. Neurology 1999, 52:566–570.
Lopera F, Ardilla A, Martinez A, et al.: Clinical features of earlyonset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997, 277:793–799.
Crook R, Verkkoniemi A, Perez-Tur J, et al.: A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998, 4:452–455.
Corder EH, Saunders AM, Strittmatter WJ, et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261:921–923.
Goate A, Chartier-Harlin MC, Mullan M, et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991, 349:704–706.
Sherrington R, Rogaev EI, Liang Y, et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995, 375:754–760.
Levy-Lahad E, Wasco W, Poorkaj P, et al.: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995, 269:973–977.
van Duinen SG, Castano EM, Prelli F, et al.: Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci U S A 1987, 84:5991–5994.
Van Broeckhoven C, Haan J, Bakker E, et al.: Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 1990, 248:1120–1122.
Levy E, Carman MD, Fernandez-Madrid IJ, et al.: Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248:1124–1126.
Koo EH, Squazzo SL: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994, 269:17386–17389.
Sastre M, Steiner H, Fuchs K, et al.: Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2001, 2:835–841.
Citron M, Oltersdorf T, Haass C, et al.: Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature 1992, 360:672–674.
De Strooper B, Annaert W: Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000, 113:1857–1870.
Weitkamp LR, Nee L, Keats B, et al.: Alzheimer disease: evidence for susceptibility loci on chromosomes 6 and 14. Am J Hum Genet 1983, 35:443–453.
Schellenberg GD, Bird TD, Wijsman EM, et al.: Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 1992, 258:668–671.
The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer’s Disease Collaborative Group. Nat Genet 1995, 11:219–222.
Rosenberg RN: The molecular and genetic basis of AD: the end of the beginning. The 2000 Wartenberg lecture. Neurology 2000, 54:2045–2054.
Finckh U, Alberici A, Antoniazzi M, et al.: Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology 2000, 54:2006–2008.
Bird TD, Levy-Lahad E, Poorkaj P, et al.: Wide range in age of onset for chromosome 1-related familial Alzheimer’s disease. Ann Neurol 1996, 40:932–936.
Kovacs DM, Fausett HJ, Page KJ, et al.: Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 1996, 2:224–229.
Thinakaran G, Harris CL, Ratovitski T, et al.: Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem 1997, 272:28415–28422.
Borchelt DR, Thinakaran G, Eckman CB, et al.: Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005–1013.
Wolfe MS, Xia W, Ostaszewski BL, et al.: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398:513–517.
Finckh U: The future of genetic association studies in Alzheimer disease. J Neural Transm 2003, 110:253–266.
Myers A, Holmans P, Marshall H, et al.: Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 2000, 290:2304–2305. Report of a candidate region on chromosome 10 for late-onset FAD. The candidate locus is in the same region as Bertram et al. [51].
Bertram L, Blacker D, Mullin K, et al.: Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 2000, 290:2302–2303. The authors reported evidence of linkage and association with markers flanking the insulin-degrading enzyme on chromosome 10. This gene is a compelling candidate because of its role in Aâ degradation.
Zannis VI, Just PW, Breslow JL: Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981, 33:11–24.
Kukull WA, Schellenberg GD, Bowen JD, et al.: Apolipoprotein E in Alzheimer’s disease risk and case detection: a case-control study. J Clin Epidemiol 1996, 49:1143–1148.
Martins RN, Clarnette R, Fisher C, et al.: ApoE genotypes in Australia: roles in early and late onset Alzheimer’s disease and Down’s syndrome. Neuroreport 1995, 6:1513–1516.
Henderson AS, Easteal S, Jorm AF, et al.: Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995, 346:1387–1390.
Corbo RM, Scacchi R: Apolipoprotein E (APOE) allele distribution in the world: is APOE*4 a ‘thrifty’ allele? Ann Hum Genet 1999, 63:301–310.
Tang MX, Stern Y, Marder K, et al.: The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998, 279:751–755.
Graff-Radford NR, Green RC, Go RC, et al.: Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002, 59:594–600.
Poirier J, Baccichet A, Dea D, Gauthier S: Cholesterol synthesis and lipoprotein reuptake during synaptic remodeling in hippocampus in adult rats. Neuroscience 1993, 55:81–90.
Nathan BP, Bellosta S, Sanan DA, et al.: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994, 264:850–852.
Siest G, Pillot T, Regis-Bailly A, et al.: Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995, 41:1068–1086.
Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622–630.
Strittmatter WJ, Saunders AM, Schmechel D, et al.: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993, 90:1977–1981.
Holtzman DM, Fagan AM, Mackey B, et al.: Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann Neurol 2000, 47:739–747.
Olichney JM, Hansen LA, Galasko D, et al.: The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 1996, 47:190–196.
Pericak-Vance MA, Bass ML, Yamaoka LH, et al.: Complete genomic screen in late-onset familial Alzheimer’s disease. Neurobiol Aging 1998, 19(suppl):S39-S42.
Pericak-Vance MA, Bass MP, Yamaoka LH, et al.: Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997, 278:1237–1241.
Pericak-Vance MA, Grubber J, Bailey LR, et al.: Identification of novel genes in late-onset Alzheimer’s disease. Exp Gerontol 2000, 35:1343–1352.
Wu WS, Holmans P, Wavrant-DeVrieze F, et al.: Genetic studies on chromosome 12 in late-onset Alzheimer disease. JAMA 1998, 280:619–622.
Rogaeva E, Premkumar S, Song Y, et al.: Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 1998, 280:614–618.
Poduslo SE, Yin X: Chromosome 12 and late-onset Alzheimer’s disease. Neurosci Lett 2001, 310:188–190.
Causevic M, Ramoz N, Haroutunian V, et al.: Lack of association between the levels of the low-density lipoprotein receptorrelated protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype. J Neuropathol Exp Neurol 2003, 62:999–1005.
Koster MN, Dermaut B, Cruts M, et al.: The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000, 55:678–684.
Blacker D, Bertram L, Saunders AJ, et al.: Results of a high-resolution genome screen of 437 Alzheimer’s disease families. Hum Mol Genet 2003, 12:23–32. A linkage study was done using a large dataset (437 AD families). This study performed parametric and non-parametric methods, finding 12 additional locations that met the criteria for suggestive linkage.
Myers A, Wavrant De-Vrieze F, Holmans P, et al.: Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet 2002, 114:235–244. Stage II of a genome-wide scan performed in a large dataset. This linkage study indicates that many potential candidate genes can be involved in familial AD.
Ertekin-Taner N, Graff-Radford N, Younkin LH, et al.: Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Science 2000, 290:2303–2304. This is the first study to use an endophenotype in an attempt to map susceptibility genes for late-onset AD. The study reports significant linkage to chromosome 10, using plasma levels of Aâ42 as a quantitative trait.
Saccone NL, Kwon JM, Corbett J, et al.: A genome screen of maximum number of drinks as an alcoholism phenotype. Am J Med Genet 2000, 96:632–637.
Porjesz B, Begleiter H, Wang K, et al.: Linkage and linkage disequilibrium mapping of ERP and EEG phenotypes. Biol Psychol 2002, 61:229–248.
Prince JA, Feuk L, Gu HF, et al.: Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 2003, 22:363–371.
Finckh U, van Hadeln K, Muller-Thomsen T, et al.: Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2. Neurogenetics 2003, 4:213–217.
Abraham R, Myers A, Wavrant-DeVrieze F, et al.: Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer’s disease. Hum Genet 2001, 109:646–652.
Ertekin-Taner N, Ronald J, Asahara H, et al.: Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Hum Mol Genet 2003, 12:3133–3143.
Olson JM, Goddard KA, Dudek DM: A second locus for verylate-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet 2002, 71:154–161.
Daw EW, Heath SC, Wijsman EM: Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees. Am J Hum Genet 1999, 64:839–851.
Meyer MR, Tschanz JT, Norton MC, et al.: APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nat Genet 1998, 19:321–322.
Tsai MS, Tangalos EG, Petersen RC, et al.: Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994, 54:643–649.
Chartier-Harlin MC, Parfitt M, Legrain S, et al.: Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and lateonset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994, 3:569–574.
Poirier J, Davignon J, Bouthillier D, et al.: Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993, 342:697–699.
Lendon CL, Martinez A, Behrens IM, et al.: E280A PS-1 mutation causes Alzheimer’s disease but age of onset is not modified by ApoE alleles. Hum Mutat 1997, 10:186–195.
Sorbi S, Nacmias B, Forleo P, et al.: Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer’s disease. Ann Neurol 1995, 38:124–127.
Haan J, Van Broeckhoven C, van Duijn CM, et al.: The apolipoprotein E epsilon 4 allele does not influence the clinical expression of the amyloid precursor protein gene codon 693 or 692 mutations. Ann Neurol 1994, 36:434–437.
Van Broeckhoven C, Backhovens H, Cruts M, et al.: APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer’s disease. Neurosci Lett 1994, 169:179–180.
Cornejo W, Lopera F, Uribe CS, Salinas M: Descripción de una familia con demencia presenil tipo Alzheimer. Acta Med Colombiana 1987, 12:55–61.
Lopera F, Arcos-Burgos M, Madrigal L, et al.: Demencia tipo Alzheimer con Agregación familiar en Antioquia, Colombia. Acta Neurológica Colombiana 1994, 10:173–187.
Pastor P, Roe CM, Villegas A, et al.: Apolipoprotein Eepsilon4 modifies Alzheimer’s disease onset in an E280A PS1 kindred. Ann Neurol 2003, 54:163–169.
Scott WK, Hauser ER, Schmechel DE, et al.: Ordered-subsets linkage analysis detects novel Alzheimer disease Loci on chromosomes 2q34 and 15q22. Am J Hum Genet 2003, 73:1041–1051. The authors considered age of onset as a covariate in a genome-wide screen, finding significant NPL LOD scores for different intervals of age on chromosomes 2q34, 9p, and 15q22.
Li YJ, Scott WK, Hedges DJ, et al.: Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002, 70:985–993.
Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry 1989, 146:577–587.
Tunstall N, Owen MJ, Williams J, et al.: Familial influence on variation in age of onset and behavioral phenotype in Alzheimer’s disease. Br J Psychiatry 2000, 176:156–159.
Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV: Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry 2003, 8:383–392.
Bacanu SA, Devlin B, Chowdari KV, et al.: Linkage analysis of Alzheimer disease with psychosis. Neurology 2002, 59:118–120. A linkage study performed in a sample of late-onset AD families with two or more members with AD plus psychotic symptoms that found a significant linkage signal on chromosome 2p and a suggestive linkage on chromosome 6q.
Rice JP, Goate A, Williams JT, et al.: Initial genome scan of the NIMH genetics initiative bipolar pedigrees: chromosomes 1, 6, 8, 10, and 12. Am J Med Genet 1997, 74:247–253.
Wang S, Sun CE, Walczak CA, et al.: Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nat Genet 1995, 10:41–46.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pastor, P., Goate, A.M. Molecular genetics of Alzheimer’s disease. Curr Psychiatry Rep 6, 125–133 (2004). https://doi.org/10.1007/s11920-004-0052-6
Issue Date:
DOI: https://doi.org/10.1007/s11920-004-0052-6